-
公开(公告)号:US20120220779A1
公开(公告)日:2012-08-30
申请号:US13503867
申请日:2010-11-02
申请人: Claire Frances Crawford , Sandrine Garcia , Jonathan Paul Graham , Sandra Jane Harling , Nicholas Paul Henley , Stephen Andrew Hermitage , John Howard Hutchinson , Trevor Raymond Keel , Andrew Kennedy , Andrew McMurtrie Mason , Mark Simon Scott , Neil Michael Smith , Nicholas Simon Stock , Yuichi Tateno , Leontine Saskia Trouw , Peter Graham Turner , Christopher John Wallis , Robert David Willacy
发明人: Claire Frances Crawford , Sandrine Garcia , Jonathan Paul Graham , Sandra Jane Harling , Nicholas Paul Henley , Stephen Andrew Hermitage , John Howard Hutchinson , Trevor Raymond Keel , Andrew Kennedy , Andrew McMurtrie Mason , Mark Simon Scott , Neil Michael Smith , Nicholas Simon Stock , Yuichi Tateno , Leontine Saskia Trouw , Peter Graham Turner , Christopher John Wallis , Robert David Willacy
IPC分类号: C07D401/14
CPC分类号: C07D403/14
摘要: The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.
摘要翻译: 本发明提供了可用于制备5-脂氧合酶活化蛋白(FLAP)抑制剂及其中间体的方法。 特别地,制备3- [3-(叔丁基硫烷基)-1- [4-(6-乙氧基 - 吡啶-3-基)苄基] -5-(5-甲基 - 吡啶-2-基 - 甲氧基 )-1H-吲哚-2-基] -2,2-二甲基 - 丙酸,3- [3-(叔丁基硫烷基)-1- [4-(6-乙氧基 - 吡啶-2-基) 吡啶-3-基)苄基] -5-(5-甲基 - 吡啶-2-基 - 甲氧基)-1H-吲哚-2-基] -2,2-二甲基 - 丙酸酯,以及可用于所述方法的中间体。
-
公开(公告)号:US20130060028A1
公开(公告)日:2013-03-07
申请号:US13698102
申请日:2011-05-17
IPC分类号: C07D239/70 , C07C227/22 , C07C229/16
CPC分类号: C07D239/70 , C07C227/08 , C07C229/16
摘要: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.
摘要翻译: 本发明涉及制备式(I)化合物的方法及其用于治疗心血管和炎性疾病如动脉粥样硬化的式(I)化合物的中间体。
-
公开(公告)号:US09447052B2
公开(公告)日:2016-09-20
申请号:US13698102
申请日:2011-05-17
IPC分类号: C07D239/70 , C07C227/08 , C07C229/16
CPC分类号: C07D239/70 , C07C227/08 , C07C229/16
摘要: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.
-
公开(公告)号:US20120053330A1
公开(公告)日:2012-03-01
申请号:US13265001
申请日:2010-04-29
申请人: Daniel Edward Patterson , Michael S. McClure , Jeremiah David Powers , Claire Frances Crawford , Malcolm Brian Berry
发明人: Daniel Edward Patterson , Michael S. McClure , Jeremiah David Powers , Claire Frances Crawford , Malcolm Brian Berry
IPC分类号: C07H17/02 , C07H15/04 , C07H15/26 , C07H15/203
CPC分类号: C07D409/04 , C07H1/00 , C07H15/04 , C07H15/203 , C07H17/02
摘要: Disclosed herein are processes for preparing glucopyranosyloxypyrazole derivatives. In particular, the present invention relates to glucopyranosyloxypyrazole derivatives having SGLT2 inhibitory activity and processes and intermediates for preparing the same.
摘要翻译: 本文公开的是制备吡喃葡萄糖氧吡唑衍生物的方法。 特别地,本发明涉及具有SGLT2抑制活性的吡喃葡萄糖氧吡唑衍生物及其制备方法和中间体。
-
-
-